CFZ monotherapy exhibited moderate therapeutic efficacy against MM, and ZMYND8 overexpression significantly suppressed tumor proliferation and augmented the efficacy of CFZ in MM (Figure 7L–N). The gene discussed is ZMYND8; the disease is Miyoshi myopathy.